- Home
- GRFS vs RVMD Comparison
GRFS vs RVMD Comparison
Compare GRFS & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRFS
- RVMD
- Stock Information
- Founded
- GRFS 1940
- RVMD 2014
- Country
- GRFS Spain
- RVMD United States
- Employees
- GRFS N/A
- RVMD N/A
- Industry
- GRFS Biotechnology: Pharmaceutical Preparations
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GRFS Health Care
- RVMD Health Care
- Exchange
- GRFS Nasdaq
- RVMD Nasdaq
- Market Cap
- GRFS 7.2B
- RVMD 7.5B
- IPO Year
- GRFS 2006
- RVMD 2020
- Fundamental
- Price
- GRFS $10.72
- RVMD $36.32
- Analyst Decision
- GRFS Hold
- RVMD Strong Buy
- Analyst Count
- GRFS 1
- RVMD 12
- Target Price
- GRFS $10.30
- RVMD $69.42
- AVG Volume (30 Days)
- GRFS 1.3M
- RVMD 1.8M
- Earning Date
- GRFS 01-01-0001
- RVMD 08-06-2025
- Dividend Yield
- GRFS 1.33%
- RVMD N/A
- EPS Growth
- GRFS 132.60
- RVMD N/A
- EPS
- GRFS 0.53
- RVMD N/A
- Revenue
- GRFS $8,744,226,659.00
- RVMD N/A
- Revenue This Year
- GRFS $5.40
- RVMD N/A
- Revenue Next Year
- GRFS $6.74
- RVMD $234.26
- P/E Ratio
- GRFS $25.84
- RVMD N/A
- Revenue Growth
- GRFS 9.32
- RVMD N/A
- 52 Week Low
- GRFS $6.19
- RVMD $29.17
- 52 Week High
- GRFS $11.14
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- GRFS 66.35
- RVMD 46.32
- Support Level
- GRFS $10.40
- RVMD $34.14
- Resistance Level
- GRFS $10.84
- RVMD $38.60
- Average True Range (ATR)
- GRFS 0.32
- RVMD 1.39
- MACD
- GRFS -0.04
- RVMD -0.02
- Stochastic Oscillator
- GRFS 73.91
- RVMD 50.43
About GRFS Grifols S.A.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.